Compare EMR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMR | SNY |
|---|---|---|
| Founded | 1890 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8B | 95.7B |
| IPO Year | 1994 | 2001 |
| Metric | EMR | SNY |
|---|---|---|
| Price | $162.17 | $46.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 11 |
| Target Price | ★ $174.82 | $53.48 |
| AVG Volume (30 Days) | 2.5M | ★ 4.4M |
| Earning Date | 11-04-2026 | 10-30-2026 |
| Dividend Yield | 1.46% | ★ 5.16% |
| EPS Growth | ★ 17.78 | N/A |
| EPS | ★ 3.45 | N/A |
| Revenue | ★ $24,412,000,000.00 | N/A |
| Revenue This Year | $5.14 | $3.80 |
| Revenue Next Year | $5.50 | $5.20 |
| P/E Ratio | $49.40 | ★ $6.14 |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $122.64 | $39.07 |
| 52 Week High | $172.00 | $52.68 |
| Indicator | EMR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 71.76 |
| Support Level | $154.30 | $45.95 |
| Resistance Level | $165.58 | $48.78 |
| Average True Range (ATR) | 5.39 | 0.86 |
| MACD | -0.39 | 0.67 |
| Stochastic Oscillator | 44.05 | 85.04 |
Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands. Emerson organizes its business into seven segments that sell a wide range of automation software, power tools, and automation hardware such as valves, gauges, and switches. In recent years, Emerson divested its climate technology and consumer businesses to become more of a pure-play industrial automation company. The automation of a factory is an enticing long-term proposition for manufacturers, helping reduce accident rates and raise uptime and productivity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.